The news of Benchmark analyst Bruce Jackson raising the price target for Genelux from $10 to $38 and maintaining a Speculative Buy rating is likely to have a positive impact on the stock price in the short term. Investors may see this as a sign of increased confidence in the company's prospects, leading to increased demand for the stock and a potential rise in its price.